WO2001074296A3 - Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists - Google Patents
Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists Download PDFInfo
- Publication number
- WO2001074296A3 WO2001074296A3 PCT/US2001/010504 US0110504W WO0174296A3 WO 2001074296 A3 WO2001074296 A3 WO 2001074296A3 US 0110504 W US0110504 W US 0110504W WO 0174296 A3 WO0174296 A3 WO 0174296A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- vascular endothelial
- endothelial growth
- factor receptor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001249736A AU2001249736A1 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
EP01922996A EP1436000A2 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
SK1530-2002A SK15302002A3 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
KR1020027013022A KR20020087453A (en) | 2000-03-31 | 2001-03-30 | Treatment of Non-Solid Mammalian Tumors with Vascular Endothelial Growth Factor Receptor Antagonists |
IL15199201A IL151992A0 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
JP2001572042A JP2004501070A (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonist |
CA002404040A CA2404040A1 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54077000A | 2000-03-31 | 2000-03-31 | |
US09/540,770 | 2000-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001074296A2 WO2001074296A2 (en) | 2001-10-11 |
WO2001074296A3 true WO2001074296A3 (en) | 2004-05-06 |
Family
ID=24156859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010504 WO2001074296A2 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1436000A2 (en) |
JP (1) | JP2004501070A (en) |
KR (1) | KR20020087453A (en) |
AU (1) | AU2001249736A1 (en) |
CA (1) | CA2404040A1 (en) |
CZ (1) | CZ20023518A3 (en) |
IL (1) | IL151992A0 (en) |
RU (1) | RU2002129574A (en) |
SK (1) | SK15302002A3 (en) |
WO (1) | WO2001074296A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0113757B1 (en) | 2000-09-11 | 2017-05-23 | Chiron Corp | quinolinone derivatives as tyrosine kinase inhibitors |
KR100847169B1 (en) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | Pyrimidineamines as angiogenesis modulators |
EP1416960A4 (en) * | 2001-07-13 | 2006-02-22 | Imclone Systems Inc | Vegfr-1 antibodies to treat breast cancer |
DK1487856T3 (en) | 2002-03-04 | 2010-10-18 | Imclone Llc | KDR-specific human antibodies and their use |
EP2573079A3 (en) | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
JP2007504122A (en) | 2003-08-29 | 2007-03-01 | ファイザー・インク | Thienopyridine-phenylacetamide and its derivatives useful as novel anti-angiogenic agents |
AP2006003619A0 (en) | 2003-12-23 | 2006-06-30 | Pfizer | Novel quinoline derivatives |
MX356412B (en) | 2011-11-02 | 2018-05-29 | Apexigen Inc | Anti-kdr antibodies and methods of use. |
-
2001
- 2001-03-30 CA CA002404040A patent/CA2404040A1/en not_active Abandoned
- 2001-03-30 RU RU2002129574/15A patent/RU2002129574A/en not_active Application Discontinuation
- 2001-03-30 CZ CZ20023518A patent/CZ20023518A3/en unknown
- 2001-03-30 AU AU2001249736A patent/AU2001249736A1/en not_active Abandoned
- 2001-03-30 JP JP2001572042A patent/JP2004501070A/en not_active Withdrawn
- 2001-03-30 WO PCT/US2001/010504 patent/WO2001074296A2/en not_active Application Discontinuation
- 2001-03-30 KR KR1020027013022A patent/KR20020087453A/en not_active Application Discontinuation
- 2001-03-30 SK SK1530-2002A patent/SK15302002A3/en not_active Application Discontinuation
- 2001-03-30 EP EP01922996A patent/EP1436000A2/en not_active Withdrawn
- 2001-03-30 IL IL15199201A patent/IL151992A0/en unknown
Non-Patent Citations (4)
Title |
---|
DEDOUSSIS GEORGE V Z ET AL: "Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line", EXPERIMENTAL CELL RESEARCH, vol. 249, no. 2, 15 June 1999 (1999-06-15), pages 269 - 278, XP002267631, ISSN: 0014-4827 * |
DIAS S ET AL: "NEUTRALIZING MOAB TO VERGF RECEPTORS INHIBIT PROFIFERATION AND MIGRATION OF A SUDSET OF HUMAN LEUKEMIAS THROUGH INTERACTION WITH VERGFR-2(KDR) AND VEGFR-1(FLT-1)", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 94, no. 10,SUPPL01PT01, 15 November 1999 (1999-11-15), pages 620A, XP001021704, ISSN: 0006-4971 * |
KATOH O ET AL: "EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR GENE, KDR, IN HEMATOPOIETIC CELLS AND INHIBITORY EFFECT OF VEGF ON APOPTOTIC CELL DEATH CAUSED BY IONIZING RADIATION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, 1 December 1995 (1995-12-01), pages 5687 - 5692, XP002915174, ISSN: 0008-5472 * |
PREWETT MARIE ET AL: "Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors", CANCER RESEARCH, vol. 59, no. 20, 15 October 1999 (1999-10-15), pages 5209 - 5218, XP002248647, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
JP2004501070A (en) | 2004-01-15 |
AU2001249736A1 (en) | 2001-10-15 |
EP1436000A2 (en) | 2004-07-14 |
KR20020087453A (en) | 2002-11-22 |
CA2404040A1 (en) | 2001-10-11 |
CZ20023518A3 (en) | 2004-04-14 |
WO2001074296A2 (en) | 2001-10-11 |
SK15302002A3 (en) | 2004-06-08 |
RU2002129574A (en) | 2004-04-20 |
IL151992A0 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2042194A3 (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | |
BG108214A (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
WO2003075841A3 (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
WO2005011734A3 (en) | Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer | |
PL319586A1 (en) | Tie-2 ligands, methods of obtaining them and their application | |
WO2005123104A3 (en) | Use of vegf inhibitors for the treatment of human cancer | |
EP2407203A3 (en) | Solid therapeutic agent for use in an implantable drug delivery device | |
WO2001082899A3 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
MXPA00004256A (en) | Vegi, an inhibitor of angiogenesis and tumor growth. | |
WO2004080425A3 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2006034455A3 (en) | Polipeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2002087555A3 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
MXPA00011248A (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. | |
EP1363629A4 (en) | Kappa opioid receptor ligands | |
HK1050860A1 (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
PL378369A1 (en) | Method of treating nausea, vomiting, retching or any combination thereof | |
WO2002076548A3 (en) | Methods and apparatus for treating diseased tissue | |
ATE375795T1 (en) | USE OF ET743 IN COMBINATION THERAPY WITH DEXAMETHASONE FOR THE TREATMENT OF CANCER | |
ZA200306541B (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. | |
WO2001074296A3 (en) | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists | |
HK1047707A1 (en) | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence | |
WO2002092016A3 (en) | Therapeutic use of rank antagonists | |
WO2001007028A3 (en) | The use of retinoid receptor antagonists in the treatment of prostate carcinoma | |
WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
MXPA02005069A (en) | Tr3 specific binding agents and methods for their use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2404040 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151992 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2001 572042 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521693 Country of ref document: NZ Ref document number: 1020027013022 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001249736 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200208051 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-3518 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15302002 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002129574 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001922996 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013022 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3518 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001922996 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001922996 Country of ref document: EP |